Science News: Nitric Oxide-Based Therapeutics for Lung Cancer

[MikeLigalig.com]

Nitric Oxide-Based Therapeutics for Lung Cancer

The inventors have demonstrated a potent tumoristatic activity of JS-36-25, a diazeniumdiolate prodrug, in both lung cancer cells in vitro and as xenografts in mice.  JS-36-25 treatment led to 85% reduction of tumor growth in vivo.  The tumoristatic potency of the compound correlated well with the level of endogenous reactive oxygen species (ROS) in the cancer cells.  Thus, in addition to potent tumoristatic activity when administered alone, this compound is predicted to have a strong synergy with therapeutics that act through generation of ROS, such as bortezomib, doxorubicin, as well as high-energy radiation.

Source: Nitric Oxide-Based Therapeutics for Lung Cancer